Systemic effects: Systemic absorption of topical triamcinolone has produced reversible the hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia and glycosuria.
Local irritation: If local irritation develops, discontinue use and institute appropriate therapy.
Skin atrophy: This is common and may be clinically significant in 3 to 4 weeks with potent preparations. Atrophy occurs most readily at sites where percutaneous absorption is high. However, Tri-am GPO (0.02%) is classified as medium potency topical corticosteroid product.
Psoriasis: Do not use topical triamcinolone as sole therapy in widespread plaque psoriasis.
Atrophic changes: Certain areas of the body, such as the face, groin and axillae, are more prone to atrophic changes than other areas of the body following treatment with triamcinolone. Frequent observation of the patient is important if these areas are to be treated.
Infections: In the presence of an infection, institute therapy with an antifungal or antibacterial agent. If a favorable response does not occur promptly, discontinue triamcinolone until the infection has been controlled. Treating skin infections with topical triamcinolone can extensively worsen the infection.
For external use only: Avoid ingestion or contact with eyes.
Occlusive therapy: Discontinue the use of occlusive dressings if infection develops and institute appropriate antimicrobial therapy.
Effect on ability to drive and use machine: Data is not available.
Use in Children: Children may be more susceptible to topical corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than adults because of a larger skin surface area to body weight ratio.
HPA axis suppression, Cushing's syndrome and intracranial hypertension have occurred in children receiving topical corticosteroids. Manifestations of adrenal suppression include linear growth retardation, delayed weight gain, low plasma cortisol levels and absence of response to adrenocorticotropic hormone (ACTH) stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches and bilateral papilledema.
Limit administration to the least amount compatible with effective therapy. Chronic corticosteroid therapy may interfere with the growth and development of children.